ERBB2 and breast carcinoma: pRIT is also being explored for breast cancer; a recent study reported that pRIT with anti-HER2-DOTA-pRIT + 177Lu-DOTA-Bn inhibited HER-2 positive breast cancer and significantly improved survival without inducing toxicity in normal tissues [48].